Delivery Order SPE2DB20D1004-SPE2DB23FF3M4

Award Date 3/1/23
Potential Completion Date 3/2/23
Potential Value $2.1K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is a delivery order valued at $2,426.43 to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the supply of GVOKE HYPOPEN 2-PK 1 MG/0.2 ML 0.2ML, a medical product, with a period of performance through October 25, 2024. The award was made by the Defense Logistics Agency (DLA), a defense agency, and is not designated as a set-aside contract. Amerisourcebergen holds a $999,999,999 Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,468.52 delivery order contract is for the supply of GVOKE HYPOPEN 2PK 0.5MG/0.1 ML 0.1ML, a medical product. The contract has a firm fixed-price pricing type and a completion date of May 9, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of the pharmaceutical distribution company Amerisourcebergen Corporation, is for the delivery of GVOKE HYPOPEN 2-PK 1 MG/0.2 ML 0.2ML, a medical product. The $1,352.16 firm fixed-price contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of May 24, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,175.89 firm fixed-price delivery order is for the supply of GVOKE HYPOPEN 2-PK 1 MG/0.2 ML 0.2ML, a medical product. The contract has an ultimate completion date of November 8, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is a Delivery Order valued at $1,263.48 for the provision of GVOKE HYPOPEN 2-PK 1 MG/0.2 ML 0.2ML pharmaceutical products. The award was made by the Defense Logistics Agency (DLA), a defense agency, on May 2, 2024, with a completion date of May 3, 2024. The contract type is Firm Fixed Price. Amerisourcebergen, a major pharmaceutical distribution company, holds a substantial Indefinite Delivery Contract (IDC)...
This federal contract award was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office division. The $3,408.62 firm-fixed-price delivery order is for the supply of the pharmaceutical product GVOKE HYPOPEN 2-PK 1 MG/0.2 ML 0.2ML, with a completion date of June 13, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 with DLA...
This is a federal contract award made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,253.83, is for the delivery of GVOKE 1 MG/0.2 ML KIT 0.2ML, a medical product. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical. This IDC serves as a primary vehicle for providing a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,397.47 contract is for the delivery of GVOKE HYPOPEN 2PK 0.5MG/0.1 ML 0.1ML medical products. The contract has an ultimate completion date of May 13, 2025. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, designated...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of GVOKE PFS 1-PK 1 MG/0.2 ML SYR 0.2ML medical supplies. The $1,722.49 firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA) Troop Support Medical, a defense agency, and has a completion date of February 5, 2024. The contract is not designated with a set-aside requirement, indicating open competition. Amerisourcebergen Drug Corp holds a significant...
This contract award to Amerisourcebergen Drug Corp's Corporate Office Division is a Delivery Order valued at $1,892.43 for the supply of GVOKE HYPOPEN 2-PK 1 MG/0.2 ML 0.2ML pharmaceutical products. The contract has an ultimate completion date of June 11, 2024 and is a Firm Fixed Price arrangement. The award is issued by the Defense Logistics Agency (DLA), a defense agency that provides logistics, acquisition, and technical services to the U.S. Armed Forces and other government agencies....
  • SPE2DB20D1004
    Indefinite Delivery Contract
  • SPE2DB20D1004-SPE2DB23FF3M4
    Delivery Order

This federal contract award is a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide GVOKE PFS 1-PK 1 MG/0.2 ML SYR 0.2ML medication. The $2,103.57 contract was awarded by the Defense Logistics Agency (DLA), a component of the Department of Defense, and has a completion date of March 2, 2023.

AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026 to provide a comprehensive range of pharmaceutical products and medical supplies supporting military and veteran healthcare programs globally. In addition, the company maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical commodities through May 2024. The contract award reviewed does not have a set-aside designation, indicating it was competitively awarded.

Generated 2/27/25, 10:44 AM